The life science industry continues to normalize after the past couple of years of increased growth. A recent report from CBRE shows that the fourth quarter of 2022 was a varied one for the Puget Sound region’s life science market. According to the report, “Despite Economic Headwinds, Life Sciences Market Finishes 2022 with Solid Fundamentals,” some of the key trends…
Under ideal conditions, cryo-electron microscopy can be used to determine protein structures at near-atomic resolution. But conditions are not always perfect. To help researchers make use of medium-resolution cryo-electron density maps, scientists in the DiMaio Lab have developed EMERALD, which is a new software tool that can accurately and automatically produce deposition-ready small molecule models into cryoEM maps. Benchmarked on over 1,000…
The more than 170 types of sarcoma come in a “great variety,” according to Lee Cranmer, MD, PhD, a Fred Hutchinson Cancer Center oncologist and researcher. One of them, chondrosarcoma, is a cancer of the cartilage, the firm-yet-flexible connective tissue that makes up our noses and ears and protects and connects our bones, allowing our skeletons to move smoothly. Sharks, whose skeletons…
The de novo design of small proteins with beta-barrel topologies has been a challenge for computational design due to the complexity inherent in these folds. In a new study appearing in PNAS, a team led by Baker Lab research scientist David E. Kim describes the successful design and characterization of four different classes of small beta barrels using Rosetta energy-based methods…
Pharmaceutical industry veteran Matthew Lumley reached out to Myosana Therapeutics after his son was diagnosed with a devastating disease. Now he’s the company’s CEO. Myosana CEO Matthew Lumley started looking into Myosana after his son Myles was diagnosed with Duchenne muscular dystrophy.
Biopharma acquisitions often come with layoffs and lab shutdowns as smaller companies get absorbed. Whether that happens to Seagen is a big question that will impact the Seattle-area biotech community. Pfizer on Monday announced plans to acquire Seagen, the Bothell, Wash.-based biotech giant, for a whopping $43 billion. It would be one of the largest acquisitions ever of a Seattle-area company, and…
Cambridge, Mass.-based biotech company Moderna is opening an office in Seattle to build up its tech capacity, the company announced Friday morning. The office will focus on artificial intelligence, cloud-based tools, and other technology applications. The company hopes to tap into Seattle’s tech talent pool, with plans to hire up to 220 workers at the new office, which opens April…
Five UW graduate students were selected for the 2022/2023 Bioengineering Cardiovascular Training Program (BCTP). Supported by a grant from the National Institutes of Health, the BCTP provides funding for predoctoral students interested in cardiovascular science and engineering to train under the guidance of mentors. The five trainees, all from bioengineering – Savannah Bifulco, Ariana Frey, Kerry Kao, Casey Kiyohara and Hao…
Pfizer is spending about $43 billion to acquire Seagen, the Bothell-based biotech giant formerly known as Seattle Genetics. Pfizer plans to let the cancer treatment developer “continue innovating,” except with more resources than it would have alone, Pfizer chair and CEO Albert Bourla told analysts. “We are not buying the golden eggs,” he said. “We are acquiring the goose that…
